Pasithea Therapeutics Corp.
KTTA Healthcare Biotechnology
In the quarter to June 2026, EPS grew 75.8% and free cash flow fell 21.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow KTTA
Pasithea Therapeutics Corp. (KTTA) EV/Sales
As of 16 October 2026, Pasithea Therapeutics Corp. (KTTA) trades at a EV/Sales of −66.3×. Over the past ten years it has ranged from −106× (December 2022) to 13.8× (November 2025); the current reading is higher than 10% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2022 | −34.6× | — |
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2022 | −32.7× | — |
| Sep 2022 | −30.5× | — |
| Jun 2022 | 0.0× | — |
| Mar 2022 | 0.0× | — |
| 1 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| KTTA Pasithea Therapeutics Corp. | −66.3× |
| LPCN Lipocine Inc. compare | −5.2× |
| ALLR Allarity Therapeutics, Inc. compare | n/m |
| RVLP RVL Pharmaceuticals PLC compare | 1.0× |
| CLVSQ Clovis Oncology, Inc. compare | 3.1× |
| CNSY Cerenome, Inc. compare | 3.3× |
| ICU SeaStar Medical Holding Corporation compare | 4.4× |
| BCDA BioCardia, Inc. compare | 30.2× |
| HIND Vyome Holdings, Inc. compare | 139× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)